Literature DB >> 20716594

Pattern of relapse and outcome of non-metastatic germinoma patients treated with chemotherapy and limited field radiation: the SFOP experience.

Claire Alapetite1, Herve Brisse, Catherine Patte, Marie Anne Raquin, Genevieve Gaboriaud, Christian Carrie, Jean Louis Habrand, Philippe Thiesse, Jean Claude Cuilliere, Valerie Bernier, M Ben-Hassel, Didier Frappaz, Marie Christine Baranzelli, Eric Bouffet.   

Abstract

Over the last two decades, chemotherapy has been introduced in protocols for patients with intracranial germinoma with the objective of reducing the volume and the dose of irradiation without compromising survival rates. The aim of this work is to critically analyze the pattern of relapse in a cohort of patients with nonmetastatic germinoma prospectively treated with chemotherapy followed by focal field radiation. Data of all germinoma patients registered in the French protocol for intracranial germ cell tumors between 1990 and 1999 were reviewed. The pattern of relapse, management, and outcome were analyzed in 10 of 60 patients who developed a recurrence after initial treatment. In 9 patients, the site of recurrence was local or loco-regional, notably in the periventricular area for 8. One patient only had isolated distant leptomeningeal relapse. The review of the sites of relapse suggests that most recurrences could have been avoided with a larger ventricular field of radiation. Treatment at first relapse included chemotherapy (10 patients), high-dose chemotherapy and stem cell transplant (8 patients), and/or radiation therapy (4 patients). Five patients experienced a second relapse. At a median follow-up of 72 months since the first relapse, 8 patients are alive in second or third remission. This review identified an excess of periventricular relapses when the focal field of radiation is used in the combined management of germinoma. These relapses are predominantly marginal or outside radiation fields. Ventricular field radiation appears a logical alternative to decrease the incidence of such relapses. Future trials should aim at better identifying patients who may benefit from local and ventricular radiation, respectively.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20716594      PMCID: PMC3018943          DOI: 10.1093/neuonc/noq093

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  22 in total

1.  Improved prognosis of intracranial non-germinoma germ cell tumors with multimodality therapy.

Authors:  P L Robertson; R C DaRosso; J C Allen
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

2.  Spinal recurrence from intracranial germinoma: risk factors and treatment outcome for spinal recurrence.

Authors:  Kazuhiko Ogawa; Yoshihiko Yoshii; Naoto Shikama; Katsumasa Nakamura; Takashi Uno; Hiroshi Onishi; Jun Itami; Yoshiyuki Shioyama; Shiro Iraha; Akio Hyodo; Takafumi Toita; Yasumasa Kakinohana; Wakana Tamaki; Hisao Ito; Sadayuki Murayama
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-29       Impact factor: 7.038

3.  Radiation therapy for intracranial germinoma: results of the German cooperative prospective trials MAKEI 83/86/89.

Authors:  M Bamberg; R D Kortmann; G Calaminus; G Becker; C Meisner; D Harms; U Göbel
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

4.  Nonmetastatic intracranial germinoma: the experience of the French Society of Pediatric Oncology.

Authors:  M C Baranzelli; C Patte; E Bouffet; D Couanet; J L Habrand; M Portas; O Lejars; P Lutz; E Le Gall; C Kalifa
Journal:  Cancer       Date:  1997-11-01       Impact factor: 6.860

5.  Radiation therapy for relapsed CNS germinoma after primary chemotherapy.

Authors:  T E Merchant; B J Davis; J M Sheldon; S A Leibel
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

6.  Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors.

Authors:  Shakeel Modak; Sharon Gardner; Ira J Dunkel; Casilda Balmaceda; Marc K Rosenblum; Douglas C Miller; Steven Halpern; Jonathan L Finlay
Journal:  J Clin Oncol       Date:  2004-05-15       Impact factor: 44.544

7.  Refining the staging evaluation of pineal region germinoma using neuroendoscopy and the presence of preoperative diabetes insipidus.

Authors:  Alyssa T Reddy; John C Wellons; Jeffrey C Allen; John B Fiveash; Hussein Abdullatif; Karen W Braune; Paul A Grabb
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

8.  Inherent diagnostic and treatment challenges in germinoma of the basal ganglia: a case report and review of the literature.

Authors:  Anita Villani; Eric Bouffet; Susan Blaser; Barbara-Ann Millar; Cynthia Hawkins; Ute Bartels
Journal:  J Neurooncol       Date:  2008-03-26       Impact factor: 4.130

9.  Neuroendoscopic findings in patients with intracranial germinomas correlating with diabetes insipidus.

Authors:  John C Wellons; Alyssa T Reddy; R Shane Tubbs; Hussein Abdullatif; W Jerry Oakes; Jeffrey P Blount; Paul A Grabb
Journal:  J Neurosurg       Date:  2004-05       Impact factor: 5.115

10.  Combined treatment modality for intracranial germinomas: results of a multicentre SFOP experience. Société Française d'Oncologie Pédiatrique.

Authors:  E Bouffet; M C Baranzelli; C Patte; M Portas; C Edan; P Chastagner; F Mechinaud-Lacroix; C Kalifa
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

View more
  40 in total

Review 1.  Recent advances in molecular biology and treatment strategies for intracranial germ cell tumors.

Authors:  Xiang Huang; Rong Zhang; Ying Mao; Liang-Fu Zhou; Chao Zhang
Journal:  World J Pediatr       Date:  2016-06-29       Impact factor: 2.764

2.  Surveillance imaging in children with malignant CNS tumors: low yield of spine MRI.

Authors:  Sébastien Perreault; Robert M Lober; Anne-Sophie Carret; Guohua Zhang; Linda Hershon; Jean-Claude Décarie; Hannes Vogel; Kristen W Yeom; Paul G Fisher; Sonia Partap
Journal:  J Neurooncol       Date:  2014-01-09       Impact factor: 4.130

Review 3.  Primary CNS germ cell tumors: current epidemiology and update on treatment.

Authors:  Jigisha P Thakkar; Lita Chew; J Lee Villano
Journal:  Med Oncol       Date:  2013-02-24       Impact factor: 3.064

4.  Loco-regional extensions of central nervous system germ cell tumors: a retrospective radiological analysis of 100 patients.

Authors:  Loïc Duron; Flavie Sadones; Philippe Thiesse; Cécile Cellier; Claire Alapetite; François Doz; Didier Frappaz; Hervé J Brisse
Journal:  Neuroradiology       Date:  2017-09-23       Impact factor: 2.804

5.  Pure germinomas of the central nervous system: treatment strategies and outcomes.

Authors:  Adam Schoenfeld; Daphne A Haas-Kogan; Annette Molinaro; Anu Banerjee; Theodore Nicolaides; Tarik Tihan; Andrew W Bollen; Nalin Gupta; Sabine Mueller
Journal:  J Neurooncol       Date:  2014-09-05       Impact factor: 4.130

6.  [Germ cell and embryonal tumors].

Authors:  W Reith; R Mühl-Benninghaus; A Simgen; U Yilmaz
Journal:  Radiologe       Date:  2014-08       Impact factor: 0.635

7.  Primary extragonadal germ cell tumor: A case report on prostate seminoma.

Authors:  Wei Zheng; Lina Wang; Deyong Yang; Kun Fang; Xiaochi Chen; Xuejian Wang; Xiancheng Li; Ziyao Li; Xishuang Song; Jianbo Wang
Journal:  Oncol Lett       Date:  2015-08-11       Impact factor: 2.967

8.  Primary Central Nervous System Germ Cell Tumors: A Review and Update.

Authors:  Kaleigh Fetcko; Mahua Dey
Journal:  Med Res Arch       Date:  2018-03-15

Review 9.  Primary intracranial germ-cell tumors in adults: a practical review.

Authors:  Jacoline E C Bromberg; Brigitta G Baumert; Filip de Vos; Johanna M M Gijtenbeek; Erkan Kurt; Anneke M Westermann; Pieter Wesseling
Journal:  J Neurooncol       Date:  2013-03-23       Impact factor: 4.130

10.  Outcomes of children with central nervous system germinoma treated with multi-agent chemotherapy followed by reduced radiation.

Authors:  Sylvia Cheng; John-Paul Kilday; Normand Laperriere; Laura Janzen; James Drake; Eric Bouffet; Ute Bartels
Journal:  J Neurooncol       Date:  2016-01-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.